Incremental cost of premature birth – a public health care payer perspective from Hungary

被引：0
|
作者：
Gábor Kovács
Zsolt Abonyi-Tóth
Petra Fadgyas-Freyler
Zoltán Kaló
机构：
[1] Eötvös Loránd University,Doctoral School of Sociology
[2] Syreon Research Institute,Center for Health Technology Assessment
[3] University of Veterinary Medicine,undefined
[4] RxTarget Ltd,undefined
[5] National Health Insurance Fund Management,undefined
[6] Semmelweis University,undefined
来源：
BMC Health Services Research | / 23卷
关键词：
Premature infant; Cost of illness; Public payer; Cost modelling;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Cost-effectiveness of lipegfilgrastim from the Mexican payer perspective
    Szende, A.
    Bussey, B.
    Szabo, E.
    Klastersky, J.
    Tomey, O.
    Mueller, U.
    Gabriel, S.
    Tang, B.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S117 - S117
  • [22] Shifting the focus from cost to value: A private payer perspective
    Shurney, Dexter W.
    JOURNAL OF MANAGED CARE PHARMACY, 2006, 12 (06): : S16 - S18
  • [23] Population perspective on birth defects: From surveillance to epidemiology to public health
    Kirby, Russell S.
    Feldkamp, Marcia
    BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY, 2006, 76 (11) : 745 - 746
  • [24] Cost of patient care in patients with ulcerative colitis in brazil: Public health perspective
    Araujo, G.
    Fonseca, M.
    VALUE IN HEALTH, 2008, 11 (03) : A84 - A84
  • [25] COST-UTILITY OF INSULIN GLARGINE COMPARED TO NPH IN TYPE DMI FROM A PUBLIC PAYER PERSPECTIVE IN POLAND
    McEwan, P.
    Woehl, A.
    Kawalec, P.
    Lis, J.
    Gierczynski, J.
    Walczak, J.
    VALUE IN HEALTH, 2008, 11 (06) : A508 - A509
  • [26] COSTS OF CANCER CARE ACROSS THE DISEASE CONTINUUM: AN ANALYSIS FROM A HEALTH PAYER PERSPECTIVE IN BRAZIL
    Dos Reis Neto, J. P.
    Busch, J.
    Stefani, S.
    VALUE IN HEALTH, 2024, 27 (06) : S392 - S392
  • [27] Cost Effectiveness of Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B from a Canadian Public Payer Perspective
    Dakin, Helen
    Sherman, Morris
    Fung, Scott
    Fidler, Carrie
    Bentley, Anthony
    PHARMACOECONOMICS, 2011, 29 (12) : 1075 - 1091
  • [28] EVOLUTION OF CANCER TREATMENT COST IN THE LAST 36 MONTHS: AN ANALYSIS FROM A HEALTH PAYER PERSPECTIVE IN BRAZIL
    Reis Neto, J. P.
    Busch, J.
    VALUE IN HEALTH, 2023, 26 (06) : S391 - S391
  • [29] Cost Effectiveness of Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B from a Canadian Public Payer Perspective
    Helen Dakin
    Morris Sherman
    Scott Fung
    Carrie Fidler
    Anthony Bentley
    PharmacoEconomics, 2011, 29 : 1075 - 1091
  • [30] Determining preventable acute care spending among high-cost patients in a single-payer public health care system
    de Oliveira, Claire
    Cheng, Joyce
    Kurdyak, Paul
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2019, 20 (06): : 869 - 878
12345